Novo Nordisk CEO says 'compounders took a part of our business away'
Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG Squawk Box Europe Podcast
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in on the impact of compounded drugs on first-quarter Wegovy sales while forecasting a rebound later this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape
Many biotechnology companies are navigating the various obstacles prevalent within the pharmaceutical industry with the implementation of artificial intelligence (AI) and machine learning (ML) technologies to optimise and streamline processes within the drug development landscape, according to speakers from the London biotechnology conference in London, UK, on 18-19 June 2025. In recent years, the pharmaceutical industry has exhibited a significant shift into digitalisation, with AI pushing for innovation across the entire drug development value chain, from accelerating drug discovery to optimising clinical trial design to ultimately improve patient outcomes. Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and human-centric in vitro models. Given the significant costs associated with drug discovery and development, achieving a successful drug candidate remains a major challenge. This complex process involves different processes such as target identification and validation, lead optimisation, and lengthy clinical trials. According to one of Novo Nordisk's speakers at the London Biotechnology conference, the company aims to utilise human data input, such as genetics, samples, and multiomics from a variety of diverse patient populations, into its target discovery engine. The AI-driven engine utilises data mining and analyses linking specific diseases to novel targets to ultimately increase the number of new targets aimed to reach the first human dose. In addition, Novo Nordisk has implemented cell image foundational models driven by deep learning to increase screening throughput derived from extensive sets of genomic data. The usage of AI and deep learning tools within the virtual assay enables large image datasets of cells to be translated into text, allowing effective mapping of the various cells by their morphology, enabling researchers to gain an understanding and effectively predict the characteristics of the cells. The implementation of AI-driven technologies has the potential to streamline many aspects of the drug development value chain, from enabling standardisation of datasets across functionalities to accelerating in vitro and in silico models and tools. As a result, pharmaceutical organisations can scale their methodologies whilst simultaneously increasing output to ultimately improve patient outcomes. "London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
3 days ago
- Yahoo
Mandatory notice of shareholding 19 June 2025
IDEX Biometrics ASA ('IDEX') discloses the following on behalf of a shareholder. Reference is made to the stock exchange notice from IDEX Biometrics ASA on 15 June 2025 regarding the share issue to personnel, and the notice regarding mandatory notification of trades on 20 June 2025. The subscription and allocation have been completed on 19 June 2025. Anders Storbråten, including associated company Pinchcliffe AS, will hold 975,635,000 shares in IDEX. Following registration of the share capital increase for the personnel placement, the ownership will represent 20.62 % of the shares and voting rights in IDEX. About this notice: This notice was issued by Kristian Flaten, CFO, on 20 June 2025 at 04:22 CET on behalf of IDEX Biometrics ASA. The information shall be disclosed according to section 4-2 of the Norwegian Securities Trading Act (STA) and published in accordance with section 5-12 of the in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
IDEX Biometrics ASA: Mandatory notification of trades
Reference is made to the stock exchange notice from IDEX Biometrics ASA on 15 June 2025 regarding the share issue to personnel. The subscription and allocation have been completed on 19 June 2025. IDEX Biometrics ASA informs of primary insider transactions as listed in the attached notifications. For further information contact: Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@ About this notice: This notice was issued by Kristian Flaten, CFO, on 20 June 2025 at 04:00 CET on behalf of IDEX Biometrics ASA. This information is subject to the disclosure requirements pursuant to Article 19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian Securities Trading Act. Attachments 2025-06-19 Annika Olsson notice 2025-06-19 Morten Opstad notice 2025-06-19 K Konsult notice 2025-06-19 Caprock notice 2025-06-19 Anders Storbraten noticeError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
